VI AAEP News November 2020
ASSOCIATION Benefit: Enlist colleagues’ expertise in AAEP’s online communities
Whether seeking advice on a difficult case, perplexed by an ethical dilemma, or wanting to offer support or guidance, you can connect, engage and draw upon the collective expertise of the membership through the AAEP’s online communities.
One component of this complimentary benefit of your membership is the Rounds, which are online forums centered on specific topics and an ideal way to exchange ideas and share knowledge with colleagues around the world. Members may subscribe to any 15 Rounds as well as the General Discussion List, which is open to all topics of interest. To join any of the discussions, visit
communities.aaep.org/home.
In addition to the Rounds, the AAEP Member Vet Talk community on Facebook is another forum through which you can solicit or offer case advice or simply share content relevant to equine veterinary medicine. More than 1,400 members participate in AAEP Member Vet Talk. To join this AAEP members-only community, simply search for the group on Facebook.
AAEP board votes to support Horseracing Integrity & Safety Act
On the recommendation of its Racing Committee, the AAEP board of directors voted in mid-October to support the Horseracing Integrity & Safety Act (H.R. 1754/S. 4547). The legislation’s chief goal is to create uniform safety and medication standards in all U.S. racing jurisdictions.
“Uniformity of rules is essential to protecting the safety of the racehorse and ensuring the integrity of the sport,” said AAEP President Dr. David Frisbie.
The AAEP’s position of support is principally based on the qualifications of the individuals chosen to serve on the HISA Nominating Committee, including equine industry leaders Dr. Jerry Black and Dr. Nancy Cox, who will select the members of the board of directors and the standing committees of the Horseracing Integrity & Safety Act Authority. However, for the horse to be best served, the AAEP will continue to advocate for additional veterinary representation on the HISA board and committees beyond the single position currently designated for each.
“In the previous version of the bill, the AAEP was a strong proponent for the governance structure to include individuals with the requisite expertise needed to capably address anti-doping and therapeutic medication regulation,” said Dr. Jeff Berk, AAEP immediate past president and Racing Committee chair. “The composition of the Authority Nominating Committee gives us confidence that the needed scientific expertise for these important positions will be considered, but we believe the breadth of knowledge needed to successfully protect equine athletes requires additional individuals.”
Regarding the race-day administration of furosemide (Lasix), the AAEP’s position continues as one of support, as the medication remains the most efficacious treatment for exercise-induced pulmonary hemorrhage (EIPH) in the horse. However, in 2019, a coalition of 20 racetracks, including hosts of Triple Crown races, along with numerous racing jurisdictions committed to restricting administration of furosemide on race day, independent of federal legislation.
“We are pleased to see in the revised legislation that the Authority will convene an advisory panel comprised of horse racing anti-doping and medication control experts to study race-day furosemide, including its impact on equine health and the integrity of competition,” added Dr. Scott Hay, AAEP president-elect and a racetrack practitio- ner. “Investigating effective management strategies for EIPH which do not require race-day medication adminis- tration has been a central goal of the AAEP’s Prescription for Racing Reform developed five years ago.”
Dr. Scott Palmer
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
